The Europe bioanalytical testing services market size was valued at USD 1.3 billion in 2023 and is projected to grow significantly to USD 2.3 billion by 2030, registering a compound annual growth rate (CAGR) of 8.9% from 2024 to 2030. This strong growth trajectory can be attributed to the increasing demand for analytical testing of biologics and biosimilars, which are becoming essential in modern pharmaceutical and therapeutic applications. The bioanalytical testing industry plays a critical role in ensuring the safety, efficacy, and quality of these advanced drugs before they reach the market.

The rapid increase in chronic diseases such as cancer, inflammatory bowel disease, and rheumatoid arthritis has amplified the need for biologic drugs, which offer targeted treatment options and improved patient outcomes. However, due to the high cost of biologics, both drug manufacturers and healthcare providers have increasingly turned their attention toward biosimilars more affordable alternatives that provide similar therapeutic benefits. Consequently, the growing research and development (R&D) activity in biosimilars has generated a strong demand for comprehensive bioanalytical testing services, including compatibility studies, protein analysis, product release testing, and stability testing. These services are vital in verifying biosimilar efficacy and safety to meet regulatory standards before market approval.

In 2023, Europe accounted for 28.9% of the global bioanalytical testing services market revenue, emphasizing the region’s importance in the global pharmaceutical landscape. The presence of advanced testing facilities and well-established research infrastructure across European countries has led to major improvements in clinical research and drug development processes. Bioanalytical testing services play an indispensable role in evaluating pharmaceutical compounds, encompassing both biologics and small molecules, through sophisticated analytical methods such as immunoassays, chromatography, and biomarker analysis. These advanced techniques are fundamental for accurate quantification, validation, and characterization of drugs during clinical development and regulatory review stages.

Europe’s strong leadership in drug discovery and development presents a major opportunity for companies offering bioanalytical testing services to expand their operational footprint in the region. The growing emphasis on understanding drug pharmacokinetics and pharmacodynamics, along with the necessity to ensure regulatory approval and commercial success, has become a key market driver. Additionally, the region’s increasing focus on personalized medicine and patient-centered healthcare has further elevated the need for precise and reliable bioanalytical testing solutions, which help tailor treatments based on individual biological profiles and genetic differences.

Key Market Trends & Insights:

• Germany held the leading revenue share in the European bioanalytical testing services market in 2023, driven by the country’s strong pharmaceutical industry, robust R&D infrastructure, and government initiatives supporting clinical trials. France is projected to record a substantial growth rate during the forecast period, supported by rising investments in biotechnology and the expansion of pharmaceutical manufacturing capabilities.
• By molecule type: The small molecule segment dominated the market with a 57.0% share in 2023, primarily due to the extensive use of small molecule drugs in chronic disease treatment and their established analytical testing methodologies. The large molecule segment is anticipated to grow at a faster CAGR of 9.5% during the forecast period, driven by the increasing R&D in biologics and biosimilars, which require more complex and specialized testing procedures.
• By workflow: The sample analysis workflow segment held the largest revenue share of 45.7% in 2023, as it represents a crucial step in determining the concentration and composition of chemical elements and compounds in drug formulations. This process ensures product consistency and regulatory compliance. The sample preparation segment is projected to advance at a CAGR of 9.3% from 2024 to 2030, owing to the rising need for high-quality sample processing techniques to ensure accurate and reproducible analytical results.
• By test type: The Absorption, Distribution, Metabolism, and Excretion (ADME) segment accounted for a substantial share of the market in 2023. ADME testing is essential in understanding how drugs behave within the human body, influencing dosage, safety, and therapeutic efficiency. The bioequivalence segment is expected to witness the fastest CAGR from 2024 to 2030, fueled by the increasing production and consumption of generic drugs and biosimilars in Europe. This testing ensures that generics and biosimilars match the efficacy and safety profiles of their original counterparts.

Order a free sample PDF of the Europe Bioanalytical Testing Services Market Intelligence Study, published by Grand View Research.

Key Companies & Market Share Insights:

Leading players in the European bioanalytical testing services market include SGS SA, ICON plc, IQVIA, Eurofins Scientific, and Syneos Health. These global and regional companies are engaged in intense competition to expand their service portfolios, strengthen client relationships, and increase market share through innovation, mergers, and strategic collaborations. 

• SGS SA, headquartered in Switzerland, is one of the prominent players offering a comprehensive range of clinical research and testing solutions. Its services cover clinical development consultancy, pharmacovigilance and drug safety, and early-phase clinical studies, including patent and clinical trials, bioequivalence, and bioavailability assessments. The company also provides verification and certification services to ensure that clients’ products comply with international quality and safety standards. In addition to testing and inspection, SGS SA delivers outsourcing, consulting, and data analytics services, helping pharmaceutical companies optimize operations and maintain regulatory compliance across different markets.

 Together, these companies are instrumental in supporting the growing European pharmaceutical and biotechnology sectors by offering high-quality, compliant, and innovative bioanalytical testing solutions that enhance the overall efficiency and reliability of drug development processes.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

In conclusion, the Europe bioanalytical testing services market is poised for strong growth, driven by the rising demand for biologics and biosimilars, alongside increasing incidences of chronic diseases. The region’s advanced research infrastructure, strong pharmaceutical base, and emphasis on regulatory compliance continue to support market expansion. Growing investments in drug discovery, personalized medicine, and biosimilar development are further enhancing the need for reliable bioanalytical testing solutions. Moreover, leading market players such as SGS SA, ICON plc, IQVIA, Eurofins, and Syneos Health are actively strengthening their service portfolios, ensuring Europe remains a key hub for high-quality clinical and analytical testing services.